In recent years, the multiple myeloma market is anticipated to grow rapidly. As per the Globocan 2020 information sheet, there were an expected 19,292,789 new cancer cases, with about 9,958,133 cancer-related deaths. Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2040, the worldwide incidence of cancer will have increased to 27.5 million new cases and 16.3 million deaths. Multiple myeloma is rare of form of cancer and one of the critical type of blood cancer which mainly affects the plasma cells. Due to rising awareness about disease symptoms, the number of diagnosis is surging in patients. This resulted in the launch of various potentially blockbuster drugs and major market players' higher treatment sophistications.
